GRG's Center For Experiential Learning

The development: In October 2022, Dostarlimab met its primary endpoint of Objective Response Rate (ORR) in a head-to-head trial against...

Both Keytruda and Opdivo are highly effective and commercially successful immunotherapies, yet Keytruda is at the forefront. In newly...